This product will give you access to the webinar only. If you would like continuing education credit for the webinar, see the table below to purchase the webinar + CME/CMLE or webinar + SAM.


This webinar reviews the updated diagnostic criteria of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms according to the recently revised WHO Classification, with emphasis on significant changes from the prior (2008) WHO Classification. New and revised entities within this group of diseases will be presented and the appropriate testing required to correctly diagnose these neoplasms will be discussed.

Speaker: Robert P. Hasserjian, MD

Host: Jennifer Dunlap, MD

Duration: 1 hr

Level of Instruction: Basic


If you would like continuing education credit, click on the links below.

Credit Type

Number of Credit Hours

Click on link to purchase:



Purchase webinar + CME/CMLE

(Free for AMP members)



Purchase webinar + SAM

(Free for AMP members)

Continuing Education Credit must be purchased and claimed by February 15, 2021.


* You may not submit SAMs and CME/CMLE credit for the same content.

You may also be interested in:


Note: Members of AMP can access this webinar at no cost. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Course Information
Course Date:
February 15, 2018
Course Objectives
  • Describe the criteria for establishing a primary diagnosis of myelodysplastic syndrome.
  • Distinguish between the subtypes of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms according to current criteria in the 2016 WHO Classification.
  • Employ ancillary testing (including flow cytometry, immunohistochemistry, cytogenetics, and molecular genetic testing) effectively in the diagnosis, classification, and prognostication of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
WHO Update 2016: Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Speaker Information
Robert P. Hasserjian MD   [ view bio ]
Individual topic purchase: Selected
Hasserjian Presentation
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $195.00